Sateesha Shivally Boregowda
Sateesha Shivally Boregowda has a total of 56 co-authors. Here are the top co-authors by number of shared publications:
- Rajamma Abburu Jayaramu
Department of Pharmacognosy, KLE College of Pharmacy, Bengaluru, KLE Academy of Higher Education and Research
14 shared publications - Afrasim Moin
Department of Pharmaceutics, College of Pharmacy, University of Hail
5 shared publications - Easwaradas Kreedapathy Girija
Department of Physics, Periyar University
5 shared publications - Amr Selim Abu Lila
Department of Pharmaceutics, College of Pharmacy, University of Ha'il, Ha'il 81442, Saudi Arabia
3 shared publications - Ankith Nallapeta Amaranatha
Department of Pharmaceutics, Acharya & BM Reddy College of Pharmacy
3 shared publications - Chandan Ravandur Shivanna
Department of Pharmaceutical Chemistry, JSS College of Pharmacy, JSS Academy of Higher Education and Research
3 shared publications
Latest Publications
- 30 June 2026
- Published by Taylor & Francis in Journal of Drug Targeting
- Vol. 34 (10) , 2122-2135
Eletriptan HBr-loaded solid lipid nanoparticle-integrated microneedles: a targeted and minimally invasive approach for migraine management
INTRODUCTIONEletriptan hydrobromide (EHBr) is a potent and clinically reliable anti-migraine agent, exerting its therapeutic effect primarily through modulation of calcitonin gene-related peptide (...
- 30 June 2026
- Published by Taylor & Francis in Journal of Drug Targeting
- Vol. 34 (10) , 2122-2135
Eletriptan HBr-loaded solid lipid nanoparticle-integrated microneedles: a targeted and minimally invasive approach for migraine management
INTRODUCTIONEletriptan hydrobromide (EHBr) is a potent and clinically reliable anti-migraine agent, exerting its therapeutic effect primarily through modulation of calcitonin gene-related peptide (...
- 1 April 2026
- Published by Taylor & Francis in Journal of Drug Targeting
- Vol. 34 (9) , 1-22
In-situ Gel Systems for Periodontitis: Advances in Localized Drug Delivery and Regenerative Therapy
Periodontitis is a chronic inflammatory condition initiated by pathogenic microbial biofilms and exacerbated by host immune responses, leading to progressive connective tissue and alveolar bone destruction and eventual tooth loss. Conventional therapies such as scaling and root planning, systemic antibiotics, and surgical interventions provide only short-term relief due to rapid drug clearance, limited penetration into deep periodontal pockets, and poor efficacy against structured biofilms. These limitations underscore the need for localized, sustained drug delivery systems capable of maintaining therapeutic concentrations at the target site. In-situ gel systems have emerged as innovative localized delivery platforms for periodontal therapy. Administered as liquids, they undergo sol-to-gel transitions in response to physiological stimuli such as temperature, pH, or ionic strength within the periodontal pocket, ensuring prolonged retention and improved therapeutic performance. Advances in polymer design, crosslinking chemistry, and fabrication methods including click reactions and supramolecular assembly have enhanced gel stability, responsiveness, and controlled release behaviour. Integration of nanotechnology, advanced biomaterials, three-dimensional bioprinting, and AI driven formulation strategies has further refined drug loading and delivery precision. Collectively, these innovations position smart in-situ gels as next generation systems for effective and sustained management of chronic periodontitis.
- 1 April 2026
- Published by Taylor & Francis in Journal of Drug Targeting
- Vol. 34 (9) , 1-22
In-situ Gel Systems for Periodontitis: Advances in Localized Drug Delivery and Regenerative Therapy
Periodontitis is a chronic inflammatory condition initiated by pathogenic microbial biofilms and exacerbated by host immune responses, leading to progressive connective tissue and alveolar bone destruction and eventual tooth loss. Conventional therapies such as scaling and root planning, systemic antibiotics, and surgical interventions provide only short-term relief due to rapid drug clearance, limited penetration into deep periodontal pockets, and poor efficacy against structured biofilms. These limitations underscore the need for localized, sustained drug delivery systems capable of maintaining therapeutic concentrations at the target site. In-situ gel systems have emerged as innovative localized delivery platforms for periodontal therapy. Administered as liquids, they undergo sol-to-gel transitions in response to physiological stimuli such as temperature, pH, or ionic strength within the periodontal pocket, ensuring prolonged retention and improved therapeutic performance. Advances in polymer design, crosslinking chemistry, and fabrication methods including click reactions and supramolecular assembly have enhanced gel stability, responsiveness, and controlled release behaviour. Integration of nanotechnology, advanced biomaterials, three-dimensional bioprinting, and AI driven formulation strategies has further refined drug loading and delivery precision. Collectively, these innovations position smart in-situ gels as next generation systems for effective and sustained management of chronic periodontitis.
- 24 March 2026
- Published by Taylor & Francis in Cutaneous and Ocular Toxicology
- Vol. 45 (3) , 1-15
Decoding psoriasis: pathological mechanisms, evolving treatments, clinical investigations, and future perspectives
1. Psoriasis represents a persistent, immune-mediated dermatological disorder characterized by inflammation and scaling plaques that result from abnormal keratinocyte proliferation. The global prev...
- 24 March 2026
- Published by Taylor & Francis in Cutaneous and Ocular Toxicology
- Vol. 45 (3) , 1-15
Decoding psoriasis: pathological mechanisms, evolving treatments, clinical investigations, and future perspectives
1. Psoriasis represents a persistent, immune-mediated dermatological disorder characterized by inflammation and scaling plaques that result from abnormal keratinocyte proliferation. The global prev...
- 30 January 2026
- Published by Taylor & Francis in Cutaneous and Ocular Toxicology
- Vol. 45 (3) , 1-13
Development and evaluation of cationic surface-modified hydroxyapatite nanoparticles for enhanced membrane permeation
This study aimed to develop positively charged, metronidazole-loaded hydroxyapatite (MZ-HP) nanoparticles with enhanced membrane interaction, permeation, and therapeutic efficacy through surface charge modulation using cetyltrimethylammonium bromide (CT). Mesoporous HP nanoparticles were synthesized from eggshell-derived calcium oxide and loaded with metronidazole, followed by CT coating (1-3.5 mM/g MZ-HP) via physisorption. Drug loading and CT adsorption were confirmed by FTIR and XRD, while SEM and TEM assessed morphology and coating induced structural changes. Particle size and zeta potential were measured using dynamic light scattering to evaluate surface charge modulation. Ex vivo porcine skin permeation studies assessed drug release and permeability. Cytocompatibility was evaluated using an MTT assay on L929 fibroblasts. MZ-HP nanoparticles were successfully formulated with a maximum loading efficiency of 87.2% at an MZ:HP ratio of 0.83 M:1 M, showing a strong positive correlation between drug to carrier ratio and loading efficiency (r = 0.90, P = 0.039). CT coating shifted the surface charge from -28.3 ± 5.12 mV (HP) to -20.5 ± 4.1 mV (MZ-HP) and further to +21.9 ± 3.3 mV (CT-MZ-HP), confirming effective charge reversal. Permeability flux increased from 1.285 to 1.582 mg/h·cm², indicating enhanced interaction with negatively charged biological membranes. Cytotoxicity studies demonstrated improved fibroblast tolerance for CT-MZ-HP (IC₅。 = 184.9 ± 3.12 µg/mL) compared to CT, inferring its short-term dermal safety and enhanced cytocompatibility. CT coated MZ-HP nanoparticles provide an effective charge-modulated nanocarrier system with enhanced trans-barrier transport, membrane interaction, intracellular access, and cytocompatibility, supporting their potential as next-generation antimicrobial delivery platforms.
- 30 January 2026
- Published by Taylor & Francis in Cutaneous and Ocular Toxicology
- Vol. 45 (3) , 1-13
Development and evaluation of cationic surface-modified hydroxyapatite nanoparticles for enhanced membrane permeation
This study aimed to develop positively charged, metronidazole-loaded hydroxyapatite (MZ-HP) nanoparticles with enhanced membrane interaction, permeation, and therapeutic efficacy through surface charge modulation using cetyltrimethylammonium bromide (CT). Mesoporous HP nanoparticles were synthesized from eggshell-derived calcium oxide and loaded with metronidazole, followed by CT coating (1-3.5 mM/g MZ-HP) via physisorption. Drug loading and CT adsorption were confirmed by FTIR and XRD, while SEM and TEM assessed morphology and coating induced structural changes. Particle size and zeta potential were measured using dynamic light scattering to evaluate surface charge modulation. Ex vivo porcine skin permeation studies assessed drug release and permeability. Cytocompatibility was evaluated using an MTT assay on L929 fibroblasts. MZ-HP nanoparticles were successfully formulated with a maximum loading efficiency of 87.2% at an MZ:HP ratio of 0.83 M:1 M, showing a strong positive correlation between drug to carrier ratio and loading efficiency (r = 0.90, P = 0.039). CT coating shifted the surface charge from -28.3 ± 5.12 mV (HP) to -20.5 ± 4.1 mV (MZ-HP) and further to +21.9 ± 3.3 mV (CT-MZ-HP), confirming effective charge reversal. Permeability flux increased from 1.285 to 1.582 mg/h·cm², indicating enhanced interaction with negatively charged biological membranes. Cytotoxicity studies demonstrated improved fibroblast tolerance for CT-MZ-HP (IC₅。 = 184.9 ± 3.12 µg/mL) compared to CT, inferring its short-term dermal safety and enhanced cytocompatibility. CT coated MZ-HP nanoparticles provide an effective charge-modulated nanocarrier system with enhanced trans-barrier transport, membrane interaction, intracellular access, and cytocompatibility, supporting their potential as next-generation antimicrobial delivery platforms.
- 5 September 2025
- Published by Taylor & Francis in Journal of Drug Targeting
- Vol. 34 (2) , 270-282
Chitosan–β-glycerophosphate thermogelling microneedles for transdermal contraceptive delivery of levonorgestrel
This study presents the development of dissolving microneedles (LMNs) incorporating a chitosan-β-glycerophosphate thermogelling system for sustained transdermal delivery of levonorgestrel (LNG) as a contraceptive. Polyvinylpyrrolidone K90 and Dextran 40 were included to enhance mechanical strength and control drug release. LMNs fabricated using PDMS molds exhibited uniform, sharp structures as confirmed by SEM. FTIR and XRD analyses demonstrated chemical compatibility and physical stability of LNG within the matrix. The optimized LMNs showed significant mechanical strength (P < 0.05) and high insertion efficiency (F = 17.83, P = 3.03 × 10-8) across Parafilm® layers and fully dissolved within 30 minutes in porcine skin. Ex vivo studies revealed sustained LNG release (70.86 ± 0.42%) over 48 hours, outperforming a topical gel (42.33 ± 0.91%). Drug release followed first-order kinetics (R2 = 0.996) and non-Fickian diffusion (n = 0.79), indicating a combined diffusion-erosion mechanism. In vivo evaluation in Wistar rats showed significant contraceptive efficacy, with reduced implantation sites (0.5 ± 0.55) and uterine thickness (3.66 ± 0.51 mm; p < 0.0001), comparable to oral LNG. These results highlight LMNs as a promising, minimally invasive platform for long-acting transdermal contraception, offering improved bioavailability, patient compliance, and therapeutic effectiveness.
- 5 September 2025
- Published by Taylor & Francis in Journal of Drug Targeting
- Vol. 34 (2) , 270-282
Chitosan–β-glycerophosphate thermogelling microneedles for transdermal contraceptive delivery of levonorgestrel
This study presents the development of dissolving microneedles (LMNs) incorporating a chitosan-β-glycerophosphate thermogelling system for sustained transdermal delivery of levonorgestrel (LNG) as a contraceptive. Polyvinylpyrrolidone K90 and Dextran 40 were included to enhance mechanical strength and control drug release. LMNs fabricated using PDMS molds exhibited uniform, sharp structures as confirmed by SEM. FTIR and XRD analyses demonstrated chemical compatibility and physical stability of LNG within the matrix. The optimized LMNs showed significant mechanical strength (P < 0.05) and high insertion efficiency (F = 17.83, P = 3.03 × 10-8) across Parafilm® layers and fully dissolved within 30 minutes in porcine skin. Ex vivo studies revealed sustained LNG release (70.86 ± 0.42%) over 48 hours, outperforming a topical gel (42.33 ± 0.91%). Drug release followed first-order kinetics (R2 = 0.996) and non-Fickian diffusion (n = 0.79), indicating a combined diffusion-erosion mechanism. In vivo evaluation in Wistar rats showed significant contraceptive efficacy, with reduced implantation sites (0.5 ± 0.55) and uterine thickness (3.66 ± 0.51 mm; p < 0.0001), comparable to oral LNG. These results highlight LMNs as a promising, minimally invasive platform for long-acting transdermal contraception, offering improved bioavailability, patient compliance, and therapeutic effectiveness.
- 1 May 2025
- Published by Springer Nature in Biomedical Microdevices
- Vol. 27 (2) , 1-12
Cyanocobalamin-loaded dissolving microneedles for enhanced transdermal delivery: development, characterization, and pharmacokinetic evaluation
This study demonstrates cyanocobalamin-loaded dissolving microneedles (CNBL-MNs) as a minimally invasive transdermal solution for managing cyanocobalamin (CNBL) deficiency, offering an alternative to intramuscular injections and oral supplements. The CNBL-MNs were developed using biodegradable, water-soluble polymers such as polyvinylpyrrolidone K25, Dextran K40, and chitosan to ensure controlled and gradual release of the CNBL. The formulation’s stability and integrity were assessed through FTIR and XRD analyses. SEM imaging revealed well-formed microneedles with a height of 800 μm, a 200 μm base diameter, and a 500 μm pitch. EDS confirmed the successful incorporation of CNBL in the microneedle array. The Parafilm® membrane insertion test revealed that the microneedles had strong mechanical properties and achieved 100% penetration efficiency. The microneedle array also demonstrated excellent (P > 0.05) flexibility and structural stability. Ex-vivo release studies showed that 88.51% of the CNBL was released over 48 h, following a first-order kinetic model. The n value of 0.51 for Korsmeyer-Peppas model indicate an anomalous transport mechanism, suggesting a combination of diffusion and erosion. The in-vivo pharmacokinetic evaluation in Wistar rats demonstrates that CNBL-MNs-2 exhibited a larger area under the curve (AUC₀–t) (61.57 ± 4.23 ng·h/mL) than the IP injection (37.04 ± 5.83 ng·h/mL), indicating significant (p > 0.05) increase in systemic availability and sustained release. The Cmax of CNBL-MNs-2 (6.10 ± 0.533 ng/mL) was comparable to that of the IP injection (6.20 ± 1.5 ng/mL), confirming efficient systemic absorption via the microneedle system. Additionally, Tmax was significantly (p > 0.05) prolonged with CNBL-MNs-2 (8 h) compared to the IP injection (2 h), suggesting a slower, more controlled CNBL release.
- 1 May 2025
- Published by Springer Nature in Biomedical Microdevices
- Vol. 27 (2) , 1-12
Cyanocobalamin-loaded dissolving microneedles for enhanced transdermal delivery: development, characterization, and pharmacokinetic evaluation
This study demonstrates cyanocobalamin-loaded dissolving microneedles (CNBL-MNs) as a minimally invasive transdermal solution for managing cyanocobalamin (CNBL) deficiency, offering an alternative to intramuscular injections and oral supplements. The CNBL-MNs were developed using biodegradable, water-soluble polymers such as polyvinylpyrrolidone K25, Dextran K40, and chitosan to ensure controlled and gradual release of the CNBL. The formulation’s stability and integrity were assessed through FTIR and XRD analyses. SEM imaging revealed well-formed microneedles with a height of 800 μm, a 200 μm base diameter, and a 500 μm pitch. EDS confirmed the successful incorporation of CNBL in the microneedle array. The Parafilm® membrane insertion test revealed that the microneedles had strong mechanical properties and achieved 100% penetration efficiency. The microneedle array also demonstrated excellent (P > 0.05) flexibility and structural stability. Ex-vivo release studies showed that 88.51% of the CNBL was released over 48 h, following a first-order kinetic model. The n value of 0.51 for Korsmeyer-Peppas model indicate an anomalous transport mechanism, suggesting a combination of diffusion and erosion. The in-vivo pharmacokinetic evaluation in Wistar rats demonstrates that CNBL-MNs-2 exhibited a larger area under the curve (AUC₀–t) (61.57 ± 4.23 ng·h/mL) than the IP injection (37.04 ± 5.83 ng·h/mL), indicating significant (p > 0.05) increase in systemic availability and sustained release. The Cmax of CNBL-MNs-2 (6.10 ± 0.533 ng/mL) was comparable to that of the IP injection (6.20 ± 1.5 ng/mL), confirming efficient systemic absorption via the microneedle system. Additionally, Tmax was significantly (p > 0.05) prolonged with CNBL-MNs-2 (8 h) compared to the IP injection (2 h), suggesting a slower, more controlled CNBL release.
- 3 April 2025
- Published by Taylor & Francis in Journal of Drug Targeting
- Vol. 33 (8) , 1399-1411
Design and formulation of fast-dissolving microneedles for the rapid transdermal delivery of lorazepam
This study investigates lorazepam-loaded dissolving microneedles (LMNs) as a fast-acting and minimally invasive treatment for status epilepticus. The LMNs were developed using a micro-moulding technique with an optimised combination of PVP K30, Dextran 40 and Pullulan. Their stability was confirmed through Fourier transform infra-red (FTIR) spectroscopy and X-ray diffraction (XRD) analysis. The Parafilm® membrane insertion test demonstrated 100% penetration efficiency, verifying their ability to effectively pierce the skin. Scanning electron microscopy (SEM) imaging revealed well-defined microneedles with precise dimensions (800 µm height, 200 µm base and 500 µm pitch). The LMNs rapidly dissolved in the subdermal layer of porcine skin. An ex vivo drug diffusion study showed that 3-5% of the encapsulated lorazepam was released within 30 min, with a cumulative release of 79.3% over 24 h. An acute dermal irritation study confirmed the biocompatibility and skin tolerance of the LMNs. Additionally, an in vivo anti-convulsant efficacy study in Albino Wistar rats subjected to maximal electroshock seizures demonstrated significant anticonvulsant effects (p < .05), confirming efficient systemic delivery of lorazepam. These findings highlight LMNs as a rapid-acting, non-invasive transdermal drug delivery system for managing status epilepticus, particularly in ambulatory care settings.
- 3 April 2025
- Published by Taylor & Francis in Journal of Drug Targeting
- Vol. 33 (8) , 1399-1411
Design and formulation of fast-dissolving microneedles for the rapid transdermal delivery of lorazepam
This study investigates lorazepam-loaded dissolving microneedles (LMNs) as a fast-acting and minimally invasive treatment for status epilepticus. The LMNs were developed using a micro-moulding technique with an optimised combination of PVP K30, Dextran 40 and Pullulan. Their stability was confirmed through Fourier transform infra-red (FTIR) spectroscopy and X-ray diffraction (XRD) analysis. The Parafilm® membrane insertion test demonstrated 100% penetration efficiency, verifying their ability to effectively pierce the skin. Scanning electron microscopy (SEM) imaging revealed well-defined microneedles with precise dimensions (800 µm height, 200 µm base and 500 µm pitch). The LMNs rapidly dissolved in the subdermal layer of porcine skin. An ex vivo drug diffusion study showed that 3-5% of the encapsulated lorazepam was released within 30 min, with a cumulative release of 79.3% over 24 h. An acute dermal irritation study confirmed the biocompatibility and skin tolerance of the LMNs. Additionally, an in vivo anti-convulsant efficacy study in Albino Wistar rats subjected to maximal electroshock seizures demonstrated significant anticonvulsant effects (p < .05), confirming efficient systemic delivery of lorazepam. These findings highlight LMNs as a rapid-acting, non-invasive transdermal drug delivery system for managing status epilepticus, particularly in ambulatory care settings.
- Open Access
- 1 December 2024
- Published by IOP Publishing in Nano Express
- Vol. 5 (4) , 045022
Eco-friendly synthesis, characterization and biological evaluation of silver nanoparticles using Ylang-Ylang oil and Tea-tree oil
Application of silver nanoparticles (AgNPs) in healthcare products to prevent/treat bacterial infections has gained popularity in the recent past. Nevertheless, the full utilization of chemically-synthesized AgNPs in biomedical field was constrained by the utilization of chemical reagents, which contaminates the environment and threatens human health. Herein, two herbal oils, i.e., Ylang-Ylang Oil (YO) and Tea Tree Oil (TO) were adopted to synthesize green-bioactive AgNPs. Besides promoting the synthesis of eco-friendly nanoparticles, the phytochemicals present in herbal oils can enhance the antibacterial properties, leading to improved efficacy of AgNPs against a broader range of pathogens. The biosynthesized YO-AgNPs and TO-AgNPs were characterized using SPR, FTIR, zeta size, zeta potential and SEM, and evaluated for their DPPH radical scavenging and antibacterial potentials. Characteristic SPR peaks for YO-AgNPs and TO-AgNPs were observed at 470 nm and 430 nm, respectively. FTIR spectra of the biosynthesized AgNPs suggested the capping of AgNPs by biomolecules present in YO and TO. The average size for YO-AgNPs was 163.1 ± 9.8 nm with zeta potential of −21.1 ± 2.8 mV, whereas the average size for TO-AgNPs was estimated as 92.4 ± 7.2 nm with zeta potential of −22.5 ± 3.6 mV. The SEM images showed polygonal YO-AgNPs, and cauliflower aggregates of spherical TO-AgNPs. Moreover, DPPH assay estimated IC50 of 47.2 μg ml−1 for YO-AgNPs, and 22.6 μg ml−1 for TO-AgNPs. The MIC50 analysis showed that both biosynthesized AgNPs were more active against gram-negative (E. coli) than gram-positive (S. aureus) strains. Most importantly, TO-AgNPs was comparatively more potent than YO-AgNPs as well as positive control (streptomycin), with an MIC50 value of 20.5 μg ml−1 and 25.9 μg ml−1 against E. coli and S. aureus, respectively. To sum up, TO-AgNPs displayed the potential to be developed into a broad-spectrum antibacterial agent, alleviating the toxicity issues associated with the use of AgNPs in healthcare products.
- 1 December 2024
- Published by IOP Publishing in Nano Express
- Vol. 5 (4) , 045022
Open AccessEco-friendly synthesis, characterization and biological evaluation of silver nanoparticles using Ylang-Ylang oil and Tea-tree oil
Application of silver nanoparticles (AgNPs) in healthcare products to prevent/treat bacterial infections has gained popularity in the recent past. Nevertheless, the full utilization of chemically-synthesized AgNPs in biomedical field was constrained by the utilization of chemical reagents, which contaminates the environment and threatens human health. Herein, two herbal oils, i.e., Ylang-Ylang Oil (YO) and Tea Tree Oil (TO) were adopted to synthesize green-bioactive AgNPs. Besides promoting the synthesis of eco-friendly nanoparticles, the phytochemicals present in herbal oils can enhance the antibacterial properties, leading to improved efficacy of AgNPs against a broader range of pathogens. The biosynthesized YO-AgNPs and TO-AgNPs were characterized using SPR, FTIR, zeta size, zeta potential and SEM, and evaluated for their DPPH radical scavenging and antibacterial potentials. Characteristic SPR peaks for YO-AgNPs and TO-AgNPs were observed at 470 nm and 430 nm, respectively. FTIR spectra of the biosynthesized AgNPs suggested the capping of AgNPs by biomolecules present in YO and TO. The average size for YO-AgNPs was 163.1 ± 9.8 nm with zeta potential of −21.1 ± 2.8 mV, whereas the average size for TO-AgNPs was estimated as 92.4 ± 7.2 nm with zeta potential of −22.5 ± 3.6 mV. The SEM images showed polygonal YO-AgNPs, and cauliflower aggregates of spherical TO-AgNPs. Moreover, DPPH assay estimated IC50 of 47.2 μg ml−1 for YO-AgNPs, and 22.6 μg ml−1 for TO-AgNPs. The MIC50 analysis showed that both biosynthesized AgNPs were more active against gram-negative (E. coli) than gram-positive (S. aureus) strains. Most importantly, TO-AgNPs was comparatively more potent than YO-AgNPs as well as positive control (streptomycin), with an MIC50 value of 20.5 μg ml−1 and 25.9 μg ml−1 against E. coli and S. aureus, respectively. To sum up, TO-AgNPs displayed the potential to be developed into a broad-spectrum antibacterial agent, alleviating the toxicity issues associated with the use of AgNPs in healthcare products.
- Open Access
Piperine-Loaded In Situ Gel: Formulation, In Vitro Characterization, and Clinical Evaluation against Periodontitis
Periodontitis is an inflammatory disorder associated with dysbiosis and characterized by microbiologically related, host-mediated inflammation that leads to the damage of periodontal tissues including gingiva, connective tissues, and alveolar bone. The aim of this study was to develop an in situ gel consisting of piperine. Eight in situ gel formulations were designed by varying the concentration of deacylated gellan gum cross-linked with sodium tripolyphosphate, and poloxamer-407. The prepared gels were evaluated for gelation temperature, gelation time, viscosity, piperine-loading efficiency, and piperine release. Finally, the optimized formula was evaluated for anti-inflammatory effectiveness among human patients during a 14-day follow-up. The optimized in situ gel formulation exhibited a gelation temperature of 35 ± 1 °C, gelling of 36 ± 1 s, excellent syringeability, and piperine loading of 95.3 ± 2.3%. This formulation efficiently sustained in vitro drug release for up to 72 h. In vivo studies revealed an efficient sol-to-gel transformation of optimized in situ gel formulation at physiological conditions, permitting an efficient residence time of the formulation within a periodontitis pocket. Most importantly, a clinical study revealed that treatment with the optimized formulation elicited a significant reduction in the mean plaque score (p = 0.001), gingival index (p = 0.003), and pocket depth (p = 0.002), and exerted a potent anti-inflammatory potential, compared to the control group. Collectively, piperine-loaded in situ gel might represent a viable therapeutic approach for the management of gingival and periodontal diseases.
Open AccessPiperine-Loaded In Situ Gel: Formulation, In Vitro Characterization, and Clinical Evaluation against Periodontitis
Periodontitis is an inflammatory disorder associated with dysbiosis and characterized by microbiologically related, host-mediated inflammation that leads to the damage of periodontal tissues including gingiva, connective tissues, and alveolar bone. The aim of this study was to develop an in situ gel consisting of piperine. Eight in situ gel formulations were designed by varying the concentration of deacylated gellan gum cross-linked with sodium tripolyphosphate, and poloxamer-407. The prepared gels were evaluated for gelation temperature, gelation time, viscosity, piperine-loading efficiency, and piperine release. Finally, the optimized formula was evaluated for anti-inflammatory effectiveness among human patients during a 14-day follow-up. The optimized in situ gel formulation exhibited a gelation temperature of 35 ± 1 °C, gelling of 36 ± 1 s, excellent syringeability, and piperine loading of 95.3 ± 2.3%. This formulation efficiently sustained in vitro drug release for up to 72 h. In vivo studies revealed an efficient sol-to-gel transformation of optimized in situ gel formulation at physiological conditions, permitting an efficient residence time of the formulation within a periodontitis pocket. Most importantly, a clinical study revealed that treatment with the optimized formulation elicited a significant reduction in the mean plaque score (p = 0.001), gingival index (p = 0.003), and pocket depth (p = 0.002), and exerted a potent anti-inflammatory potential, compared to the control group. Collectively, piperine-loaded in situ gel might represent a viable therapeutic approach for the management of gingival and periodontal diseases.